文献速递慢性肾脏病

γ-氨基丁酸类似物与阿片类药物疗法治疗慢性肾脏病相关瘙痒的随机对照试验Meta分析

Meta-Analysis of Randomized Controlled Trials on Gamma-Aminobutyric Acid Analogues and Opioid-Based Therapies for CKD-Associated Pruritus.
PubMed 文献 · Kidney Int Rep · 2025-06-24

该Meta分析纳入截至2025年1月22日检索的27项随机对照试验、共2836例慢性肾脏病相关瘙痒患者,评估γ-氨基丁酸类似物与阿片类疗法的疗效与安全性;γ-氨基丁酸类似物显著降低10厘米视觉模拟量表与5-D瘙痒评分且不良事件无显著增加,阿片受体靶向治疗显著降低最严重瘙痒数字评定量表、5-D瘙痒、Skindex-10与100毫米视觉模拟量表但不良事件或药物不良反应显著更高;作者认为尤其地非法林的潜力显著,但μ受体拮抗剂相关不良事件更高,且多数结果异质性大需谨慎解读。

要点

  • γ-氨基丁酸类似物显著降低10厘米视觉模拟量表与5-D瘙痒评分,不良事件或药物不良反应无显著增加。
  • 阿片受体靶向治疗显著降低最严重瘙痒数字评定量表、5-D瘙痒、Skindex-10与100毫米视觉模拟量表,但不良事件或药物不良反应显著更高。
  • 作者认为地非法林等疗法潜力显著,但多数结果异质性大,解读需谨慎。

核心结论

  • 作者认为γ-氨基丁酸类似物与阿片类药物疗法尤其地非法林在减轻慢性肾脏病相关瘙痒强度与改善生活质量方面有显著潜力。
  • 作者指出阿片类药物疗法尤其μ受体拮抗剂如纳曲酮与纳布啡与更高的不良事件或药物不良反应发生率相关。
  • 作者指出鉴于多数结果观察到显著异质性,解读应谨慎。

研究设计与样本

  • 研究为Meta分析,检索PubMed、Embase与Scopus截至2025年1月22日。
  • 仅纳入报告对瘙痒严重程度评分治疗效应的随机对照试验,涵盖单维量表与多维量表。
  • 共分析27项随机对照试验、涉及2836例慢性肾脏病相关瘙痒患者。
  • 结果采用随机效应模型合并,提供加权均数差与相对危险度及95%置信区间。

主要发现

  • γ-氨基丁酸类似物治疗与10厘米视觉模拟量表及5-D瘙痒评分显著更大程度降低相关,不良事件或药物不良反应发生率无显著增加。
  • 阿片受体靶向治疗显著降低最严重瘙痒数字评定量表、5-D瘙痒、Skindex-10与100毫米视觉模拟量表。
  • 阿片受体靶向治疗的不良事件或药物不良反应发生率显著更高,尤其涉及胃肠道问题以及睡眠障碍等神经系统疾病。

局限性

  • 作者指出多数结果观察到显著异质性,解读应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD)-associated pruritus (CKD-aP) is one of the most distressing symptoms of patients with CKD, adversely affecting their quality of life and survival. This study aimed to investigate the efficacy and safety of gamma-aminobutyric acid (GABA) analogues and opioid-based therapies in patients with CKD-aP. METHODS: The eligible studies were searched from PubMed, Embase, and Scopus up to January 22, 2025. Only randomized controlled trials (RCTs) that reported the treatment effect on pruritus severity scores were included, focusing on both unidimensional scales and multidimensional scales. The results were synthesized using a random-effect model and provided weighted mean difference (WMD) and relative risk (RR) with a 95% confidence interval (CI). RESULTS: A total of 27 RCTs involving 2836 patients with CKD-aP were analyzed. Treatment with GABA analogues was associated with significantly greater reductions in 10-cm visual analog scale (VAS) and 5-D itch scores with nonsignificant increased incidence of adverse events (AEs) or adverse drug reactions (ADRs). In addition, opioid receptor-targeting treatments significantly decreased worst itch numeric rating scale (WI-NRS), 5-D itch, Skindex-10, and 100-mm VAS, but showed significantly higher rates of AEs or ADRs, particularly related to gastrointestinal issues, as well as neurological disorders such as sleep disturbances. CONCLUSION: Our results suggest that GABA analogues and opioid-based therapies, particularly difelikefalin, have significant potential in alleviating itch intensity and improving the quality of life of patients with CKD-aP. However, opioid-based therapies, especially those involving μ-receptor antagonists such as naltrexone and nalbuphine, are associated with a higher incidence of AEs or ADRs. Given the substantial heterogeneity observed in most of the results, interpretation should be approached with caution.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wathanavasin W, Thammathiwat T, Susantitaphong P, et al. Meta-Analysis of Randomized Controlled Trials on Gamma-Aminobutyric Acid Analogues and Opioid-Based Therapies for CKD-Associated Pruritus. Kidney Int Rep. 2025. PMID: 40980656. doi:10.1016/j.ekir.2025.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。